Atara Biotherapeutics is a biotechnology company located in New York, New York, specializing in the development of off-the-shelf, allogeneic T-cell immunotherapies. Based in the heart of Manhattan, this company focuses on innovative treatments targeting cancer, autoimmune disorders, and viral diseases. By leveraging advanced cell therapy technologies, Atara Biotherapeutics aims to create novel therapeutic options that address unmet medical needs in these challenging health areas.

The company’s approach centers on harnessing the power of T-cells, a critical component of the immune system, to fight disease. Unlike traditional therapies that may require customization for each patient, Atara Biotherapeutics develops therapies that can be produced in advance and made readily available for multiple patients. This off-the-shelf model allows for potentially faster treatment delivery and broader accessibility. Their research and development efforts are supported by a team of scientists and clinicians dedicated to advancing the understanding and application of immunotherapy.

Located at 135 East 57th Street, Atara Biotherapeutics serves as a hub for cutting-edge biotechnological innovation within New York City’s vibrant medical and scientific community. The company collaborates with various partners and institutions to enhance its pipeline and translate laboratory discoveries into clinical applications. With a focus on improving patient outcomes, Atara Biotherapeutics continues to push the boundaries of cell-based treatment options.

For inquiries or additional information, the company can be reached by phone at 646-661-4588. Atara Biotherapeutics remains committed to exploring the potential of T-cell therapies and contributing to the evolving landscape of biotechnology in New York and beyond.